Building a $33B Digital Health Juggernaut
Dexcom generates more than $4 billion in annual revenue and has a market cap north of $30 billion, making it one of the biggest digital health companies in the world. And it all started with a better way to measure blood sugar.
In this episode, Halle is joined by Kevin Sayer, CEO of Dexcom, the company that pioneered continuous glucose monitoring (CGM). Under Kevin’s leadership, Dexcom scaled from $40 million to $4 billion in revenue, became the standard of care for people with diabetes, and is now expanding into consumer wellness with its direct-to-consumer product, Stelo.
We cover:
📈 How Dexcom scaled 100x without relying on acquisitions
📱 Why real-time glucose data is so powerful—and who needs it beyond diabetes
🤝 Building trust with both doctors and patients
⚖️ What GLP-1s mean for Dexcom’s business
📦 The shift from regulated med device to consumer tech
📊 The future of metabolic health (and what else their sensors might measure next)
—
About our guest:
Kevin Sayer is the Chairman of the Board of Directors and Chief Executive Officer of Dexcom.
Kevin assumed the role of CEO in January 2015 and became Chairman of the Board in July 2018. Kevin has also served as our President since 2011. He held the role of Chief Operating Officer from January 2013 until January 2015. Kevin has served as a member of Dexcom’s Board of Directors beginning in November 2007, prior to his role as Chairman and CEO.
Prior to leading Dexcom, Kevin held various management positions in his prior roles. He served as Chief Financial Officer of Biosensors International Group, Ltd., Executive Vice President and Chief Financial Officer of Specialty Laboratories, Inc., Chief Financial Officer of MiniMed, Inc., and Vice President and General Manager of Medtronic MiniMed after the acquisition of MiniMed by Medtronic.
Kevin is a Certified Public Accountant (inactive) and received a Bachelor’s degree and a Master's degree in Accounting and Information Systems from Brigham Young University.
Listen:
